BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 23284757)

  • 1. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.
    Janaka SK; Lucas TM; Johnson MC
    J Virol; 2011 Nov; 85(22):11945-54. PubMed ID: 21917962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
    Lucas TM; Lyddon TD; Cannon PM; Johnson MC
    J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.
    Christodoulopoulos I; Droniou-Bonzom ME; Oldenburg JE; Cannon PM
    Retrovirology; 2010 Jan; 7():4. PubMed ID: 20102634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
    Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
    Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
    Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
    J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.
    Petit SJ; Blondeau C; Towers GJ
    J Gen Virol; 2011 Dec; 92(Pt 12):2937-2948. PubMed ID: 21900423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.